 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||
|
SELECT PUBLICATIONS
Buske C et al. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma; Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASH 2006; Abstract 482.
Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract
Czuczman MS et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17(1):268-76. Abstract
Hiddemann W et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc ASH 2003;Abstract 352
Hochster HS et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG/CALGB Intergroup E1496 trial. Proc ASCO 2007; Abstract 8004.
Marcus R et al. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin’s lymphoma. Proc ASH 2003;Abstract 87.
Pfreundschuh M et al. Six vs eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Proc ASH 2006(108); Abstract 205.
Press OW et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24(25):4143- 9. Abstract
Solal-Celigny P et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-65. Abstract
Van Oers M et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 Intergroup trial. Blood 2006;15 108(10):3295-301. Abstract
Vose JM et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001;19(2):389-97. Abstract
| Table of Contents | Top of Page |
